Advertisement

FDA Expands Use of Abraxane to Advanced Pancreatic Cancer — Physician’s First Watch

Medical News |
September 9, 2013

FDA Expands Use of Abraxane to Advanced Pancreatic Cancer

By Kristin J. Kelley

The chemotherapy drug nanoparticle albumin-bound paclitaxel (brand name, Abraxane) is now approved for metastatic pancreatic cancer, the FDA announced late last week. The drug, previously approved for both breast and lung cancers, should be used in combination with gemcitabine.

In a randomized study of some 860 patients, those who received Abraxane plus gemcitabine lived an average of 1.8 months longer than those given gemcitabine alone.

Pneumonitis and sepsis were among the potentially serious side effects of Abraxane plus gemcitabine.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement